Latest

Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆

Updated 13 Aug 2026 · ClinicalTrials.gov

Clinical Trials in Bengaluru

← All India trials

Every active and recruiting clinical study with an investigative site in India — searchable by condition, sponsor, phase and location. Refreshed daily from the ClinicalTrials.gov registry.

2

Recruiting now

4

Active studies

Active Phase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi · started 2024-04-16

📍 Bengaluru · Chandigarh · Delhi · Gurgaon · Mangaluru · Nagpur

NCT06372145 on ClinicalTrials.gov ↗

Active Phase 3

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Heart Failure, Systemic Inflammation
Novo Nordisk A/S · started 2024-04-01

📍 Vijayawada · Visakhapatnam · Vadodara · Belagavi · Bengaluru · Mysuru

NCT06200207 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca · started 2023-12-14

📍 Bengaluru · Hyderabad · Jaipur · Kanpur · Kochi · Kolkata

NCT06129864 on ClinicalTrials.gov ↗

Recruiting

Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr

Cervical Cancer
CHA University · started 2022-08-01

📍 Bengaluru

NCT05421650 on ClinicalTrials.gov ↗

No trials match your search.

Browse by location

New Delhi · 19 Mumbai · 18 Hyderabad · 17 Bangalore · 14 Kolkata · 11 Nagpur · 11 Chandigarh · 9 Jaipur · 9 Ahmedabad · 8 Belagavi · 7 Pune · 7 Kochi · 6

Browse by condition

Heart Failure · 4 Chronic Obstructive Pulmonary Dis… · 2 Tuberculosis · 2 Breast Cancer · 2

Cite this page

Priya Life Science (2026). Clinical Trials in India Tracker. Available at: https://priyalifescience.com/clinical-trials-india/city/bengaluru (Accessed: 13 August 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — studies listing at least one Indian site, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician.